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Abstract 
Glioblastoma (GBM) is one of the most aggressive forms of cancer. It has been proposed that the presence 
within these tumors of a population of cells with stem-like features termed Glioma Initiating Cells (GICs) is 
responsible for the relapses that take place in the patients with this disease. Targeting this cell population is 
therefore an issue of great therapeutic interest in neuro-oncology. We had previously found that the 
neurotrophic factor MIDKINE (MDK) promotes resistance to glioma cell death. The main objective of this 
work is therefore investigating the role of MDK in the regulation of GICs.  
Methods: Assays of gene and protein expression, self-renewal capacity, autophagy and apoptosis in cultures of 
GICs derived from GBM samples subjected to different treatments. Analysis of the growth of GICs-derived 
xenografts generated in mice upon blockade of the MDK and its receptor the ALK receptor tyrosine kinase 
(ALK) upon exposure to different treatments. 
Results: Genetic or pharmacological inhibition of MDK or ALK decreases the self-renewal and tumorigenic 
capacity of GICs via the autophagic degradation of the transcription factor SOX9. Blockade of the MDK/ALK 
axis in combination with temozolomide depletes the population of GICs in vitro and has a potent anticancer 
activity in xenografts derived from GICs. 
Conclusions: The MDK/ALK axis regulates the self-renewal capacity of GICs by controlling the autophagic 
degradation of the transcription factor SOX9. Inhibition of the MDK/ALK axis may be a therapeutic strategy to 
target GICs in GBM patients. 
Key words: glioblastoma, Midkine, ALK receptor tyrosine kinase, autophagy, SOX, combinational therapies  
Introduction 
Grade IV astrocytoma, or glioblastoma (GBM) is 
one of the most aggressive forms of cancer. GBM 
patients typically exhibit a median survival after 
diagnosis of 12-15 months [1, 2]. These tumors 
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frequently exhibit molecular alterations in several 
oncogenes and tumor suppressor genes affecting 
some of the most relevant signaling pathways 
involved in the control of tumorigenesis, including 
through tyrosine kinase receptors (RTKs). Enhanced 
RTK signaling is thought to contribute to the high 
invasiveness and resistance to most anticancer 
therapies exhibited by GBMs [1, 2]. The standard 
treatment for these tumors is based on surgical 
resection, which frequently is not complete due to the 
proximity of the tumor mass to vital brain regions, 
followed by radiotherapy and concomitant chemo-
therapy with the alkylating agent temozolomide 
(TMZ) [1-3]. Unfortunately, almost all patients with 
GBM relapse after a few months. The identification 
within these tumors of a restricted cell population 
with characteristics of stem cells [termed Glioma 
stem-like cells or Glioma Initiating Cells (GICs)] 
exhibiting a high resistance to present anti-glioma 
therapies led to postulate the currently-accepted 
theory that GICs are directly involved in GBM 
relapse. Therefore one of the strategies to improve the 
survival of patients with this disease should be based 
on elimination of GICs [2, 4-7]. 
 The neurotrophic and developmental factor 
MIDKINE (MDK) belongs to the PLEIOTROPHIN/ 
MIDKINE family and has been shown to participate 
in the regulation of many different physiological 
functions [8-10]. Specifically, MDK has been 
implicated in the regulation of neural stem cells and 
embryonic CNS development [11]. MDK effects have 
been proposed to rely on the stimulation of several 
different receptors [10] although a significant number 
of the functions of the protein has been attributed to 
its ability to stimulate the ALK receptor tyrosine 
kinase (ALK) [10, 12]. In a cancer context, MDK has 
been proposed to promote resistance to anticancer 
treatments via ALK stimulation [13]. In addition, 
MDK levels have been shown to be increased in 
different cancers [14-18]. Specifically, our group and 
others previously demonstrated that enhanced MDK 
levels correlated with worse prognosis in GBM 
patients [13, 19], thereby suggesting that this growth 
factor may play a role in glioma generation and 
progression. 
In this work we investigated whether the 
MDK/ALK axis is involved in the regulation of GICs 
biology. Our findings demonstrate that MDK plays a 
key role in the maintenance of the stem-like and 
tumorigenic properties of GICs via ALK stimulation. 
We also found that inhibition of the MDK/ALK axis 
may be used as a therapeutic strategy to target the 
population of GICs as treatment for GBM.  
Materials and Methods 
Reagents 
Mouse monoclonal anti-MDK antibody (N- 
terminal region, MDK Ab.) and purified recombinant 
MDK were kindly provided by LYRAMID (Sydney, 
Australia). Both reagents were resuspended in PBS. 
Doxycycline (Dox) and puromycin were purchased 
from Sigma (St. Louis, MO, USA) and resuspended in 
DMEM and PBS, respectively. NVP-TAE 684 (TAE) 
was kindly provided by Sergey A. Lakatosh at the 
Gause Institute of New Antibiotics (Moscow, Russia) 
or purchased from MedChem Express (Sollentuna, 
Sweeden). Crizotinib and lorlatinib were kindly 
donated by Pfizer (New York, NY, USA). Pure THC 
and CBD were obtained from THC Pharm Company 
(Frankfurt, Germany). TMZ and lactacystin were 
purchased from Calbiochem-Merck (Darmstadt, Ger-
many). E64d and pepstatin A (PA) were purchased 
from Enzo Life Science (Farmingdale, NY, USA).  
Cell culture 
Glioblastoma patient-derived cultures enriched 
in cells with stem-like properties (that in this work we 
named cultures of Glioma Initiating Cells, GICs) were 
obtained from human GBM tumor samples from the 
Spanish National Cancer Center (CNIO, Madrid, 
Spain) biobank (GH2 and GH11-GICs), from Hospital 
12 de Octubre (Madrid, Spain) (12O12-GICs) and from 
Hospital Clinico San Carlos (Madrid, Spain) 
(HCO1-GICs). All procedures involving samples of 
human origin were performed with the approval of 
the corresponding ethical committees from each 
institution as well as of the ethical committee of 
Complutense University (Madrid, Spain). Briefly, 
GICs cultures were obtained by using the following 
procedure: tumor samples were mechanically and 
enzymatically dissociated with 0.12 mg/ml of 
collagenase type Ia from Clostridium histolyticum 
(#C9722, Sigma) for 2 h at 37 ºC and filtered using a 
100 μm nylon filter (Millipore, Burlington, MA, USA). 
Cells were then plated and maintained as 
non-adherent neurospheres for at least 3 consecutive 
passages (with the aim of enriching the cultures in 
cells with stem-like properties) in a DMEM:Ham’s 
F-12 media (Lonza, Basel, Switzerland) supplemented 
with 1% penicillin–streptomycin (Lonza), 5 mM 
HEPES buffer (Lonza), 2 mM ultraglutamine (Lonza), 
20 ng/ml EGF and FGFb (Gibco, Carlsbad, USA), 2 
μg/ml heparin sodium salt (Sigma), 1% B27 
(Invitrogen, Carlsbad, USA) and 1 µg/ml leukemia 
inhibitory factor (LIF, Millipore). Enrichment in GICs 
was analyzed by testing the expression of a panel of 
stem cell markers in these cultures. To induce 
differentiation of GICs, supplements were removed 
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and cells were cultured in DMEM containing 10% FBS 
and 1% penicillin–streptomycin.  
HEK293T and the human glioma U87MG 
(ATCC® HTB-14™) cell lines were purchased from 
ATCC (Manassas, Virginia, USA) and cultured in 
DMEM containing 10% FBS and 1% penicillin–
streptomycin. U87-neurospheres cultures (U87-GICs) 
were generated by incubation in DMEM:Ham’s 
F-12-supplemented media as described above and 
maintained as non-adherent cultures for at least 3 
consecutive passages. All cell cultures were incubated 
at 37 ºC, 5% CO2. Experiments were performed using 
GICs cultures between passages 3 and 20. 
Unless otherwise indicated, drugs were 
prepared in DMSO for in vitro experiments. Control 
incubations contained the same amount of DMSO and 
no significant effect was observed in any of the 
parameters determined throughout this study at the 
final concentration used (< 0.5%, v/v). 
Analysis of tumor-sphere growth capacity of 
GICs cultures 
Cultures of GICs were plated at a density of 104 
cells/ml (passage 0, P0) and incubated with the 
different treatments for 5 days. The spheres formed 
were then dissociated, counted (passage 1, P1) and 
equal number of cells re-plated and incubated again 
with the corresponding treatments for 5 additional 
days. This procedure was repeated for two 
consecutive passages (passage 2, P2). Data from these 
experiments are expressed as the total number of cells 
counted upon disaggregation of spheroid cultures in 
each passage and are represented as the mean 
fold-change from the number of cells plated at P0. 
Limiting Dilution Assays (LDA) 
Limiting dilution assays were performed as 
previously described [20]. Briefly, cultures of GICs 
were plated at density of 104 cells/ml and incubated 
with the different treatments for 5 days. Spheres 
formed were dissociated and plated in fresh medium 
in the absence of the drug in 96-well plates at different 
densities (200, 100, 50, 20 and 10 cells per well, 
respectively). One week later, tumorsphere formation 
was evaluated: wells in which there was at least one 
neurosphere were considered positive. Data in the 
corresponding representations indicates the fraction 
of cells with ability to generate new spheres cultures. 
Graphs were obtained using the ELDA software 
application [20] that adjusts the data obtained in each 
experimental condition to the limiting dilution model. 
In these graphs the slopes of the depicted solid lines 
correspond to the fraction of cells with ability to 
generate new spheres cultures. A lower slope value 
indicates a lower fraction of cells with capacity to 
generate new spheres. Dotted lines represent the 95% 
confidence interval. 
Human MIDKINE ELISA detection 
Soluble MDK levels were determined by ELISA 
Kit for human MDK detection (LYRAMID) according 
to manufacturer’s instructions. 
Quantitative real-time PCR 
RNA was isolated by using the Trizol reagent 
(Invitrogen) following manufacturer’s instructions 
and including a DNAse digestion step with the 
RNAse-free DNAse kit (Qiagen, Maryland, USA). 
cDNA was obtained from 1 µg of RNA using the 
Transcriptor Reverse Transcriptase (Roche, Basel, 
Switzerland). Real-time quantitative PCR assays were 
performed using the FastStart Master Mix (Roche) 
and probes were obtained from the Universal Probe 
Library Set (Roche). Primer sequences and Roche’s 
probes corresponding to each pair of primers can be 
found in Supplementary Table 1 (Methods 
Information). Amplifications were run in a 7900 
HT-Fast Real- Time PCR System (Applied Biosystems, 
Carlsbad, CA, USA). Each value was normalized 
using 18S, TBP or GAPDH RNA levels as reference. 
Gene expression was quantified by the delta-delta Ct 
method. 
Light field microscopy 
Images were obtained in an Eclipse TE300 
microscope (Nikon, Minato, Tokyo, Japan) coupled to 
a digital camera DS-U2 (Nikon). 
Immunofluorescence staining and confocal 
microscopy 
Neurospheres were plated onto glass cover slips 
pre-treated with Matrigel (BD Bioscience, NY, USA, 
dilution 1:100 in DMEM medium), fixed with 4% 
paraformaldehyde (Sigma) for 10 min, permeabilized 
and blocked with 10% goat serum PBS containing 
0.25% Triton X-100 (Sigma) for 1 hour and incubated 
with the corresponding primary antibodies 
[Supplementary Table 2 (Methods Information)] in 5% 
goat serum overnight at 4 ºC. Cover slips were 
washed with PBS and incubated with the 
corresponding anti-rabbit or anti-mouse Alexa-488 or 
Alexa-594-conjugated secondary antibodies (Life 
Technologies, Carlsbad, CA, USA) at a 1:1000 (v/v) 
dilution at room temperature for 1 hour and nuclei 
were stained with DAPI (Roche) for 10 min. Finally, 
cover slips were mounted with mowiol (Calbiochem- 
Merck) and images were obtained in a Leica TCS SP2 
confocal microscope (Leica, Germany). 
Samples from tumor xenografts were dissected, 
frozen in Tissue-Tek OCT compound (Sakura, CA, 
USA) and cryostat sectioned (8 μm) using a Leica CM 
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1950 cryostat (Wetzlar, Germany). Sections were fixed 
in acetone (Panreac, Darmstadt, Germany) for 10 min 
at room temperature, permeabilized and blocked as 
previously described and incubated with the 
corresponding primary antibodies (Supplementary 
Table 2 (Methods Information)). Images were 
obtained in an Axiovert 135 microscope (Carl Zeiss, 
Thornwood, NY, USA). 
TUNEL assay 
TUNEL was performed as previously described 
[21] using the in situ Cell Death Detection Kit (Sigma).  
Quantification of LC3 vesicles  
The quantification of LC3 vesicles was 
performed using the ImageJ JavaScript 
AUTOCONTER as previously described [22]. The 
ratio between the sum of the LC3 vesicle areas 
(ΣAves) and the total cell area (Acell) was calculated 
per each cell. At least 11 cells per treatment from 3 
independent experiments were analyzed.  
Western blot 
Western blot analysis was performed following 
standard methods. Briefly, cells were lysed in a buffer 
containing 50 mM Tris-HCl, 0.1% Triton X-100, 50 mM 
NaF, 10 mM sodium glicerophosphate, 5 mM sodium 
pyrophosphate, 1 mM sodium orthovanadate, 
1µg/ml leupeptine, 1 mM EDTA and EGTA, 200 µM 
β-mercaptoetanol and 1 µM microcystin. Tumor 
samples were lysed on RIPA buffer supplemented 
with 1 mM sodium orthovanadate, 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF), 2 µg/µl 
aprotinin and 2 µg/µl leupeptin. Lysates were 
centrifuged at 12,000 rpm for 15 min. Protein 
concentration was determined by Bradford assay. 
Proteins were electrophoretically separated in 
SDS-polyacrylamide gels (Biorad, Hercules, CA, 
USA), transferred onto PVDF membranes (Biorad), 
blocked with a 5% skimmed milk solution or 5% 
bovine serum albumin (BSA, Sigma) in TBS-T [10 mM 
Tris-HCl pH 7.5, 100 mM NaCl, and 0.1% Tween-20 
(Panreac)] for 1 h at room temperature and incubated 
overnight at 4 ºC with the corresponding primary 
antibody (a list of the primary antibodies used in the 
Western blot analyses included in this study can be 
found in Supplementary Table 3 (Methods 
Information)). The day after, membranes were 
washed with TBS-T and incubated for 1 h at room 
temperature with their corresponding secondary 
antibody [HRP-conjugated anti-rabbit or anti-mouse 
(GE Healthcare Dharmacon, Chicago, USA)]. 
Immunoreactivity was detected using the enhanced 
chemiluminescence (ECL) system (Biorad). 
Densitometric quantification was performed with 
ImageJ software. 
Immunoprecipitation 
Cells were lysed using a HEPES lysis buffer 
containing 40 mM HEPES pH 7.5, 120 mM NaCl, 
1mM EDTA, 10 mM sodium pyrophosphate, 10 mM 
sodium glycerophosphate, 50 mM sodium fluoride, 
0.5 mM sodium orthovanadate, 0.3% CHAPS, and 
supplemented with 1 mM benzamidine and 0.1 mM 
PMSF freshly added. Cell lysates (1–2 mg) were 
precleared by incubation with 10 μl of protein 
G-sepharose (GE Healthcare Dharmacon) at 4 ºC for 
30 min. The lysate extracts were then incubated 
overnight at 4 ºC with 5-10 μl of protein G–sepharose 
covalently coupled to 5–10 μg of the primary anti-LC3 
(ref. L8918, Sigma) or anti-SOX9 (ref. ab76997, Abcam) 
antibodies or an unspecific IgG (negative control). 
Immunoprecipitates were washed 4 times with 
HEPES lysis buffer followed by 2 washes with HEPES 
kinase buffer (25 mM HEPES pH 7.5 and 50 mM KCl), 
resuspended in 30 μl of sample buffer (without 
2-mercaptoethanol) and filtered through a 0.22 
μm-pore size Spin-X filter (Sigma). Then 
2-mercaptoethanol was added to a concentration of 
1% (v/v). Samples were subjected to electrophoresis 
and immunoblot analysis following standard 
procedures. 
Lentiviral particles generation and 
transduction 
For lentiviral particle generation (shATG5), 
HEK293A were plated in 60 cm2 dishes and 
transfected with a human TRIPZ ATG5 lentiviral 
doxycycline-inducible shRNA plasmid (clone ID 
V2THS_249282, Thermo Scientific, Waltham, MA, 
USA) using the standard calcium-phosphate 
transfection protocol [23]. 48 h later, supernatant was 
collected, filtered using a 0.45 µm diameter low 
protein binding filter (Millipore) and mixed up with 
Lenti-X™ Concentrator (Clontech, Fremon, CA, USA) 
at a 1:3 (v/v) ratio overnight at 4 ºC. Lentiviral 
particles were precipitated, resuspended in DMEM 
and stored at -80 ºC. Titer of lentiviral particle stocks 
was determined by plating HEK293T cells in 24-well 
plates transfected with serial dilutions of the viral 
stock and subsequent counting of the number of 
Turbo GFP or RFP positive cells for each well. 
Lentiviral vectors encoding target-specific 
doxycycline-inducible shRNA constructs targeting 
MDK (Thermo Scientific; SMART choice inducible 
lentiviral shRNA) or ALK (GE Healthcare 
Dharmacon; SMARTvector human inducible shRNA) 
were used. The three sequences provided for 
targeting MDK were GCTCGTTAGCTTTAATCAA 
(shMDK23), TTGGAGCCGACTGCAAGTA (shMDK 
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31) and GGGATTCTGGGAAGCTTGA (shMDK39). 
After analysis of the silencing efficacy of each of these 
sequences, shMDK39 was selected. The two 
sequences provided for targeting ALK were TAGTTG 
GGGTCATAGATGT (shALK03) and CCTGTGAGCT 
GGAGTATTC (shALK06). After analysis of the 
silencing efficacy of each of these sequences, shALK03 
was selected.  
To stably knock-down the expression of ATG5 in 
GICs-cultures we used a SMART-pool of concentrated 
transduction-ready human lentiviral particles con-
taining 3 target-specific inducible shRNA constructs 
[mature antisense: AAGTTTCTGAGATTGTATG, 
TTCGTTAAGGAAAGATGGG and ATCTCACTAAT 
GTCTTCTT)] (ref. RHS11852-EG9474, GE Healthcare 
Dharmacon) or a SMART-pool of concentrated 
transduction-ready human lentiviral particles 
containing 3 target-specific constitutive shRNA 
constructs (sc-41445-V, Santa Cruz Biotechnology, 
Dallas, Texas, USA). To stably knock-down ATG7 we 
used a SMART-pool of concentrated transduction- 
ready human lentiviral particles containing 3 target- 
specific constitutive shRNA constructs (sc-41447-V, 
Santa Cruz Biotechnology). A doxycycline-inducible 
(GE Healthcare Dharmacon) or a constitutive (Santa 
Cruz Biotechnology) scrambled shRNA construct 
were used as controls. 
Briefly, GICs cultures were plated at a density of 
104 cells/ml in a supplemented GIC media with 
hexadimethrine bromide (Sigma) at a final 
concentration of 2.5 mg/ml. Cells were subsequently 
infected with control- or target-specific shRNA 
lentiviral particles. Two days later, the medium was 
removed and replaced by complete medium without 
hexadimethrine bromide. Finally, to select the clones 
stably expressing the shRNAs, the cells were 
incubated with puromycin (Gibco) at a concentration 
of 1 to 5 µg/ml. To induce shRNA expression, 
doxycycline (Dox) at a final concentration of 1 µg/ml 
was added. All experiments with cells transduced 
with doxycycline-inducible shRNAs were performed 
in cell cultures that had been exposed to doxycycline 
for at least two passages to ensure the appropriate 
expression of the corresponding shRNAs. 
Nucleofection with plasmids 
For SOX9 knock-down or overexpression, 
GICs-cultures were nucleofected with a plasmid 
expressing a SOX9-selective shRNA [(pLKO shSOX9 
(#40644, Addgene, Cambridge, MA, USA)] or a 
plasmid encoding a murine form of SOX9 [(pWPXL 
SOX9 (#36979, Addgene)] respectively. A pLKO 
plasmid expressing a scramble shRNA (#8453, 
Addgene) or a pWPXL GFP (#12257, Addgene) were 
used as controls (control plasmids, CP). Briefly, 5 x 105 
GICs were plated, centrifuged at 1100 rpm for 5 min, 
resuspended with 50 µl of nucleofector kit (Lonza) 
and electroporated with 3 µg of the corresponding 
plasmid using the NucleofectorTM 2b Device (Lonza). 
All experiments with plasmid-nucleofected cells were 
performed at least 4 days after electroporation to 
ensure the appropriate shRNA or protein expression 
was taking place. 
Flow cytometry 
(0.2-1) x 106 GICs for each experimental 
condition were fixed with 4% paraformaldehyde 
(Sigma) for 10 min, permeabilized with Perm/Wash 
buffer 1x (BD Bioscience) for 20 min and subsequently 
incubated with the Nestin-PE (ref.656805, clone 10C2, 
Biolegend, San Diego, CA, USA) antibody for 30 min 
at 22 ºC in darkness. Finally, samples were washed 
with the Perm/Wash buffer 1x and analyzed by flow 
cytometry (LSR Fortessa, BD Bioscience/Becton 
Dickonson and Company, New Jersey, USA) using 
the FlowJow software v 7.6.5 (Tree star, Ashland, 
USA). 
Generation of tumor xenografts and drug 
treatment 
For subcutaneous xenografts, 2 x 106 12O12-GICs 
resuspended 1:1 (v/v) in 100 μl of supplemented 
GICs-medium and matrigel (BD Bioscience) were 
subcutaneously injected in the right flank of 
5-week-old female nude mice (Harlan Laboratories, 
Indiana, USA). Tumors were daily measured with an 
external caliper, and volume was calculated as (4π/3) 
x (width/2)2 x (length/2). When tumors had reached 
an average size of 200 mm3, animals were randomly 
assigned to different groups and treatments with the 
corresponding drugs commenced. 
Crizotinib and lorlatinib were diluted in PBS or 
water with a pH range of 2.75-3.25 respectively and 
orally administered by using an oral gavage. TMZ 
was diluted in PBS supplemented with 5 mg/ml BSA 
and intraperitoneally (I.P.) administered. The 
corresponding diluent was used as vehicle for each 
treatment. Once the treatments were completed, 
animals were sacrificed, and tumors excised for 
further analyses. 
For the generation of intracranial xenografts, 
12O12-GICs with less than 3 passages were infected 
with lentiviral particles expressing a shC (control), 
shMDK or shALK and subsequently selected using 
puromycin (1 µg/ml). One week before injection, 
shRNA expression was induced by treatment with 
doxycycline (1 µg/ml). 0.75 x 105 infected 12O12-GICs 
resuspended in 4 μl of supplemented GIC-medium 
were stereotactically injected into the right cerebral 
hemisphere of nude mice (coordinates A-P: +1 mm; 
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M-L: -2 mm; D-V: –3 mm relative to bregma) by using 
a 10 µl Hamilton syringe 701RN (Hamilton, Nevada, 
USA). Animals were previously anesthetized with 
isoflurane and subsequently treated with a mixture of 
buprenorphine (0.1 mg/kg) and meloxicam (1 
mg/kg). To ensure that shRNA expression was 
maintained along the in vivo experiment, animals 
injected with 12O12 GICs shMDK/shALK (+Dox) 
were fed with a doxycycline-enriched diet (Sodispan, 
Madrid, Spain). The monitoring of tumor growth by 
magnetic resonance imaging (MRI) was performed at 
the Nuclear Magnetic Resonance Centre of 
Complutense University (Madrid, Spain) using a 
BIOSPEC BMT 47/40 (Bruker, Ettlingen, Germany). 
Tumor volume was calculated using the ImageJ 
software from T1-weighted images.  
Patient dataset and bioinformatics analysis 
Kaplan-Meier survival analysis plots were 
obtained from “GlioVis” [24], a website application 
for data visualization and analysis to explore gene 
expression datasets from studies involving patients 
with brain tumors. This tool expresses the ‘survival’ 
package in R. The following datasets were evaluated 
to correlate MDK expression and patient survival: 
Rembrandt study [25] (microarray data, containing 
information from 225 low-grade glioma and 219 GBM 
samples, respectively); Gravendeel study [26] 
(microarray data, containing information from 117 
low-grade glioma and 159 GBM samples, 
respectively); Lee Y. study [27] (microarray data type, 
containing information from 191 GBM samples). 
Additional survival analysis in correlation with 
MDK expression were obtained using the “The 
Pathology Atlas” section of the “Human Protein 
Atlas” [28]. More than 100 million of Kaplan-Meier 
plots were analyzed by the “Human Protein Atlas” 
portal to correlate gene expression levels and survival 
time. Median expression levels were used as a cutoff. 
Best separation cutoffs are presented for each gene in 
each cancer type. 
Statistical analysis 
Unpaired Student’s t test or U Mann-Whitney 
test were used when two independent groups were 
analyzed. For multiple comparison, analysis of 
variance (ANOVA) test was performed (one-way or 
two-way ANOVA) with a Tukey’s post hoc test. 
χ²-test was used for LDA experiments. The survival of 
nude mice was analyzed by Kaplan-Meier curves and 
differences were compared by log-rank test analysis. 
Data are expressed as mean ± standard error of the 
mean (SEM). P values of < 0.05 were considered 
statistically significant. Analyses were performed 
using the GraphPad Prism 6.0 software. 
Study approval 
All procedures involving samples of human 
origin were performed with the approval of the 
corresponding ethical committees from each 
institution as well as of the ethical committee of 
Complutense University/Hospital Clínico San Carlos. 
Samples from GBM patients used in this study were 
originally obtained upon signature of the 
corresponding written informed consent (which had 
been previously approved by the Institutional Ethical 
Committee). Samples were incorporated in the 
corresponding institutional biobanks. All procedures 
involving animals were performed with the approval 
of the corresponding ethical committees from 
Complutense University and Madrid region 
according to European regulations. 
Results 
MDK regulates the self-renewal capacity of 
GICs  
Analysis of GBM patient’s datasets from 
published studies revealed the existence of a clear 
correlation between high MDK expression and worse 
prognosis in GBM patients (Figure S1A-F). Therefore, 
we asked whether MDK may play an oncogenic role 
in GBM via a positive regulation of GICs. We used a 
panel of GICs cultures derived from GBM samples, 
which were extensively characterized in vitro to 
confirm the expression of bona-fide (glioma) stem cell 
markers (Supplementary Table 1 and Figure S2A-B). 
MDK protein levels present in the medium (Figure 1A 
and Figure S2C) as well as MDK mRNA levels (Figure 
S2D) were dramatically increased in GICs-enriched 
cultures (hereafter named GICs cultures) as compared 
with the levels of this neurotrophic factor in the 
corresponding cultures of serum-differentiated 
glioma cells. Moreover, genetic inhibition of MDK by 
using a doxycycline-inducible MDK-selective shRNA 
(Figure S2E-F) [note that controls of silencing of this 
and other panels are included in the supplementary 
Figures], reduced the size of the neurospheres 
generated with GICs (Figure 1B). Likewise, genetic 
inhibition of MDK or removal of MDK from the 
medium by using an anti-MDK neutralizing antibody 
(Figure S2G) strikingly reduced the capacity of GICs 
to generate new neurosphere cultures during two 
consecutive passages (Figure 1C and Figure S2H) and 
inhibited the self-renewal capacity, as determined by 
the limited dilution assay [LDA [20]](Figure 1D and 
Figure S2I).  
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Figure 1. MDK regulates the self-renewal capacity and tumorigenic properties of GICs. (A) MDK protein levels (as determined by ELISA) in the medium of GICs cultures or of 
their corresponding serum-differentiated cells. Data correspond to MDK concentration (ng/ml) and are expressed as mean concentration ± SEM (n=3). *P < 0.05; **P < 0.01 from 
serum-differentiated cells. (B) Effect of MDK genetic inhibition [by treating with doxycycline (+Dox) cells stably transduced with a doxycycline-inducible MDK-selective (shMDK) shRNA] on 
the morphology of GH2, 12O12 and HCO1-GICs cultures. Representative images obtained by phase-contrast microscopy are shown. Values in each image correspond to the neurosphere’s 
area (nm2) and are expressed as mean fold change ± SEM. At least 4-5 neurospheres were analyzed for each experimental condition in each GIC culture. *P < 0.05 from shMDK (-Dox). (C) 
Effect of MDK genetic inhibition or incubation with an anti-MDK antibody (MDK Ab., 40 μg/ml) on the growth of GH2-GICs (n=3). **P < 0.01 from vehicle or shMDK (-Dox) cells. (D) Effect 
of MDK genetic inhibition (+Dox) on the self-renewal ability (as determined by LDA) of GH2, 12O12 and HCO1-GICs (n=2). *P < 0.05; ***P < 0.001 from shMDK (-Dox). (E-F) Effect of MDK 
depletion by incubation with an anti-MDK antibody (MDK Ab., 40 μg/ml, 72h) (GH2-GICs, panel E) or by expressing a doxycycline-inducible shMDK (+Dox; HCO1-GICs, panel F) on the 
mRNA levels of a panel of stem cell associated genes. Data are expressed as mean fold change from vehicle (panel E) or shMDK (-Dox) (panel F)-treated cells (reference) ± SEM (n=3). *P < 
0.05; **P < 0.01; ***P < 0.001 from vehicle-treated cells (panel E) or from shMDK (-Dox) (panel F). (G) Effect of the incubation with an anti-MDK antibody (MDK Ab., 40 μg/ml, 72 h) on 
NESTIN expression (as determined by immunostaining) of 12O12-GICs. Scale bar: 20 μm. (H) Procedure to generate intracranial xenografts with 12O12 shMDK-GICs. (I) Effect of MDK 
genetic inhibition [shMDK (+Dox)] on the size of glioma xenografts generated by intracranial injection of 7.5 x 104
 
12O12 shMDK-GICs (n=12). Representative MRI images 6 weeks after the 
injection are shown (left panel). Tumor volume is expressed as mean ± SEM (right panel). *P < 0.05 from 12O12 shMDK (-Dox) tumors. (J) Effect of MDK genetic inhibition [shMDK (+Dox)] 
on the survival of tumor-bearing mice. Kaplan-Meier plot (n=12). ***P < 0.001 from 12O12 shMDK (-Dox) tumors. 
Theranostics 2020, Vol. 10, Issue 11 
 
 
http://www.thno.org 
5127 
The observed reduction in GIC neurosphere 
generation in the absence of MDK correlated with a 
striking reduction in the expression of a panel of stem 
cell markers (Figure 1E-G and Figure S3A-F). 
Specifically, we verified that MDK depletion 
decreased the number of NESTIN and MUSASHI 
(MSl1) (two well-established biomarkers of stemness 
[6, 29])-positive cells in neuro-sphere cultures (Figure 
1G and S3D-E). Likewise, abrogation of MDK 
signaling markedly diminished protein levels of these 
two stem cell markers (Figure S3E). 
 To investigate the role of MDK in the regulation 
of the tumorigenic capacity of GICs in vivo, we 
injected 12O12 GICs expressing a doxycycline- 
inducible MDK-selective shRNA into the striatum of 
immunodeficient mice (Figure 1H). Doxycycline- 
induced knock-down of MDK expression (Figure 
S3G) delayed the onset (Figure S3H) and inhibited the 
growth (Figure 1I) of 12O12 GICs-derived orthotopic 
xenografts. Likewise, MDK genetic depletion 
enhanced the survival of the mice bearing tumors 
generated with these cells (Figure 1J and Figure 
S3I-L).  
MDK effects on GICs rely on ALK stimulation 
The ALK receptor tyrosine kinase (ALK) has 
been proposed to mediate MDK actions in cancer cells 
[10, 12, 30]. We found that ALK protein levels were 
increased in GICs when compared with their 
serum-differentiated counterparts (Figure S4A). In 
addition, MDK treatment increased the 
phosphorylation of ALK as well as of some of its 
well-established downstream targets (STAT3, ERK 
and AKT)[31, 32] in GH2 GICs (Figure 2A), and this 
effect was prevented by ALK pharmacological 
inhibition using NVP-TAE 684 (TAE [33]) (Figure 
S4B). Likewise, MDK silencing decreased the 
phosphorylation of ALK and its downstream targets 
(Figure 2B), supporting the idea that MDK effects in 
GICs rely on ALK stimulation. In agreement with this 
hypothesis, we found that the genetic inhibition of 
ALK or the pharmacological blockade of this receptor 
using TAE as well as crizotinib and lorlatinib (two 
drugs that are currently being used in clinical 
oncology to target ALK)[34] reduced the ability to 
form neurospheres during two consecutive passages 
(Figure 2C and Figure S4C) and inhibited the 
self-renewal capacity (Figure 2D and Figure S4D) of 
three different cultures of GICs. This decrease in the 
stem-like properties of GICs was consistent with a 
downregulation of the expression of a panel of stem 
cell markers upon ALK inhibition (Figure 2E and 
Figure S4E-F). Specifically, ALK pharmacological 
blockade decreased the number of NESTIN (Figure 
2F) and MSI1 (Figure S4G)-positive cells, supporting 
the notion that the MDK-ALK axis is involved in the 
regulation of the stem cell properties of GICs. In line 
with this idea, doxycycline-induced ALK silencing 
inhibited tumor growth and increased the survival of 
animals bearing GICs-derived intracranial xenografts 
(Figure 2G-H).  
MDK/ALK inhibition-induced effects on GICs 
rely on SOX9 degradation 
The SOX family of transcription factors plays a 
pivotal role in the regulation of the maintenance of the 
stem-like properties of GICs [35]. Accordingly, we 
found that blockade of the MDK/ALK axis in GICs 
cultures triggered a sustained downregulation of 
several stem cell markers including various SOXs, 
which correlated with the observed decrease in the 
self-renewal capacity of GICs (Figure 1E, 1F, 2E and 
Figure S5A-B). Specifically, we found that MDK/ALK 
inhibition for 72 h or longer timepoints led to 
decreased expression (associated with a 
transcriptional regulation) of several SOX family 
members with oncogenic activity including SOX2, 
SOX4 and SOX9 (Figure S5A-B). In addition, analysis 
of SOXs protein levels at early time points (24 h after 
the blockade of the MDK/ALK axis, a time point 
which changes in the transcriptional regulation of 
these genes were not observed yet) showed a 
consistent reduction of SOX9 but not of SOX2 or SOX4 
or of other stem cell markers in GICs cultures (Figure 
3A, Figure S5C). In agreement with the idea that SOX9 
plays a key regulatory role in the triggering of the 
events that lead to the loss of the stem-like properties 
of GICs upon blockade of the MDK/ALK axis, SOX9 
silencing mimicked the effect of MDK/ALK axis 
inhibition in GICs and resulted in a lower efficiency of 
neuro-sphere formation (Figure 3B and Figure S5D) as 
well as in a clear reduction in the mRNA levels of 
several stem cell markers, including SOX2 and SOX4 
(Figure 3C and Figure S5E). Conversely, re-expression 
of a murine form of SOX9 in GICs cultures (Figure 
S5F) prevented the inhibition of the self-renewal 
capacity triggered by the genetic (Figure S5G) or 
pharmacological (Figure 3D) inhibition of MDK, as 
well as the decrease in the expression of several stem 
cell markers evoked by incubation with an anti-MDK 
neutralizing antibody (Figure 3E). Likewise, 
MDK/ALK inhibition decreased the expression levels 
of c-MYC and CYCLIND1, two well-stablished SOX9 
targets (Figure S5H). These observations strongly 
support the idea that the MDK/ALK signaling axis 
regulates the maintenance of the stem-like properties 
of GICs by controlling SOX9 protein levels. 
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Figure 2. MDK/ALK axis plays a relevant role in the maintenance of the stem-like properties and the tumorigenic capacity of GICs. (A) Effect of the 
incubation with exogenous MDK (MDK, 50 ng/ml) on the phosphorylation of ALK (pALK), AKT (pAKT), ERK (pERK) and STAT3 (pSTAT3) of GH2-GICs at different time points. 
Left panel: a representative Western blot is shown (n=3). Right panel: Data correspond to the densitometric analysis of the levels of each phosphorylated protein relative to total 
levels of that protein and are expressed as the mean fold change ± SEM relative to vehicle-treated cells (n=3). *P < 0.05 and ***P < 0.001 from MDK 0 min-treated cells. (B) Effect 
of MDK genetic inhibition [by treating with doxycycline (+Dox) cells stably transduced with a doxycycline-inducible MDK-selective (shMDK) shRNA] on the phosphorylation of 
ALK (pALK), AKT (pAKT), ERK (pERK), and STAT3 (pSTAT3) of GH2-GICs. Left panel: a representative Western blot is shown (n=3). Right panel: data correspond to the 
densitometric analysis of the levels of each phosphorylated protein relative to total levels of that protein and are expressed as the mean fold change ± SEM relative to shMDK 
(-Dox)-treated cells (n=3). ***P < 0.001 from (-Dox)-treated cells. (C) Effect of ALK genetic inhibition (by treating with doxycycline (+Dox) cells stably transduced with a 
doxycycline-inducible shALK) or incubation with TAE (1 μM) or crizotinib (0.75 μM) on the growth of GH2-GICs (n=3). ***P < 0.001 from vehicle or shALK (-Dox) cells. (D) 
Effect of ALK genetic inhibition (+Dox) or incubation with TAE (0.75 μM) on the self-renewal ability (as determined by LDA) of GH2, 12O12 and HCO1-GICs (n=2). **P < 0.01 
from shALK (-Dox.) cells or HCO1 vehicle-treated cells; ***P < 0.001 from GH2 vehicle-treated cells. (E) Effect of ALK genetic inhibition (by treating with doxycycline (+Dox) 
cells stably transduced with a doxycycline-inducible shALK) on the mRNA levels (as determined by qPCR) of a panel of stem cell associated genes in 12O12 shALK-GICs. Data 
are expressed as mean fold change from shALK (-Dox)-treated cells (reference) ± SEM (n=3). *P < 0.05; **P < 0.01; ***P < 0.001 from 12O12shALK (-Dox). (F) Effect of the 
incubation with TAE (0.75 µM, 72 h) on NESTIN expression (as determined by immunofluorescence) of HCO1-GICs. Values in each photomicrograph correspond to the 
percentage of NESTIN-positive cells relative to the total number of nuclei. Representative photomicrographs are shown (n=3). ***P < 0.001 from vehicle-treated cells. Scale bar: 
20 μm. (G) Effect of ALK genetic inhibition on the size of glioma xenografts (MRI) generated by intracranial injection of 7.5 x 104 12O12 shALK-GICs. Representative MRI images 
6 weeks after the injection are shown (left panel). Tumor volume is expressed as mean ± SEM (right panel) (n=8-11). **P < 0.01 from 12O12 shALK (-Dox) tumors. (H) Effect 
of ALK genetic inhibition on the survival of tumor-bearing mice. Kaplan-Meier plot (n=12). ***P < 0.001 from 12O12 shALK (-Dox) tumors. Inset: Effect of doxycycline (+Dox) 
on ALK protein levels of 12O12 shALK cultures determined right before their intracranial injection. 
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Figure 3. MDK/ALK signaling axis regulates the maintenance of the stem-like properties of GICs by controlling SOX9 protein levels. (A) Effect of the 
incubation with an anti-MDK antibody (MDK Ab., 40 μg/ml) or TAE (0.75 μM) for 24 h on SOX2, SOX4, SOX9 and CD133 protein levels of GH2-GICs. Left panel: a 
representative Western blot experiment is shown (n=5). Right panel: densitometric analysis of SOX9, SOX2 and SOX4 protein levels (mean fold change from vehicle ± SEM; n=5 
for SOX9 and SOX2 and n=3 for SOX4). **P < 0.01 and ***P < 0.001 from vehicle-treated cells. NS: statistically non-significant differences. (B) Effect of SOX9 genetic inhibition 
[by nucleofection with a plasmid encoding a shcontrol (shC) or a SOX9-selective (shSOX9) shRNA] on the self-renewal ability (as determined by LDA) of GH2-GICs (n=3) **P 
< 0.01 from shC cells. (C) Effect of SOX9 genetic inhibition (72 h) on mRNA levels of a panel of stem cell associated genes (as determined by qPCR) of GH2-GICs. Data are 
expressed as mean fold change from shC cells (reference) ± SEM (n=3). *P < 0.05; **P < 0.01; **P < 0.001 from shC cells. (D) Effect of the incubation with an anti-MDK antibody 
(MDK Ab., 40 μg/ml) and nucleofection with a control plasmid (CP), or a plasmid encoding a murine SOX9 (SOX9) on the self-renewal ability (as determined by LDA) of 
GH2-GICs (n=2). #P < 0.05 from MDK Ab.-treated CP cells. Full χ2 statistical analysis is included in LDA statistics section within the supplementary materials. (E) Effect of the 
incubation with an anti-MDK antibody (MDK Ab., 40 µg/ml) on the mRNA levels of NESTIN, MUSASHI-1 (MSI1) and SOX9 (as determined by qPCR) of GH2-GICs nucleofected 
with a control plasmid (CP) or a plasmid encoding a murine SOX9 (SOX9) (72 h). *P < 0.05 from vehicle CP-treated cells. 
 
SOX9 levels have been shown to be regulated 
transcriptionally and by the poly-ubiquitylation and 
subsequent degradation of this protein in the 
proteasome [35, 36]. However, MDK/ALK axis 
inhibition did not modify SOX9 mRNA levels at 24 h 
(the timepoint at which the initial reduction of SOX9 
protein levels was observed) (Figure S6A). Likewise, 
pharmacological blockade of the proteasome by 
lactacystin did not prevent the decrease of SOX9 
protein levels triggered by the blockade of the 
MDK/ALK axis (Figure S6B) suggesting that these 
mechanisms are not responsible for SOX9 stability in 
this model. 
Blockade of the MDK/ALK axis induces 
autophagy in GICs  
ALK is coupled to the activation of the AKT/ 
MTORC1 pathway [30, 31] and we found that MDK/ 
ALK axis inhibition decreased the phosphorylation of 
AKT (Figure 2A, 2B and S4B), of TSC2 (a well 
stablished AKT downstream target that when 
phosphorylated contributes to stimulate the activity 
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of the MTORC1 complex) as well as of the ribosomal 
protein S6 (Figure S6C), a direct MTORC1 target. 
Since inhibition of the MTORC1 axis triggers 
autophagy and this process is one of the main cellular 
mechanisms responsible for protein degradation [37], 
we asked if the inhibition of the MDK/ALK axis 
stimulated autophagy in GICs.  
 
Figure 4. Blockade of the MDK/ALK axis in GICs induces the autophagic degradation of SOX9. (A) LC3 and NESTIN immunostaining of GH2-GICs cells incubated 
with an anti-MDK antibody (MDK Ab., 40 μg/ml, 24 h) (n=3). Representative images (with a high magnification photomicrograph of the squared-pointed area of MDK Ab.-treated 
cells) are shown. Scale bar: 20 μm. (B) Quantification of the percentage of cells with LC3 dots within the population of NESTIN-positive or negative GH2-GICs (n=3). *P < 0.05 
***P < 0.001 from vehicle-treated cells; ##P < 0.01 from MDK Ab.-treated NESTIN-negative cells. ND: Non-detectable. (C) Effect of the incubation with an anti-MDK antibody 
(MDK Ab., 40 μg/ml) on MUSASHI1 (MSI1), CD133 and LC3-I/II protein levels of GH2-GICs stably transduced with a doxycycline-inducible shATG5 at different time points 
(n=3). A representative experiment is shown. (D) Effect of the incubation with an anti-MDK antibody (MDK Ab., 40 µg/ml) and the genetic inhibition of autophagy on the 
self-renewal ability (as determined by LDA) of GH2-GICs (n=2). #P < 0.05 from GH2 shATG5 (-Dox.) MDK Ab.-treated cells. Full χ2 statistical analysis is included in LDA statistics 
section within the supplementary materials. (E-F) Effect of the incubation with an anti-MDK antibody (MDK Ab., 40 μg/ml; 24 h, panel E) or TAE (0.75 μM, 24 h, panel F) on 
SOX9 and LC3-I/II protein levels of shC or shATG5-transduced GH2-GICs cultures untreated or pretreated with E64d (10 μM) and pepstatin A (PA, 10 μg/ml) for 1 h. A 
representative Western blot (upper panels) and the corresponding densitometric quantifications (bottom panels) are shown (n=5). **P < 0.01 from vehicle-treated cells; #P < 0.05 
from MDK Ab.-treated shC cells. 
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In support of this hypothesis, blockade of 
MDK/ALK signaling led to a consistent increase in 
autophagy at 24 h, as determined by the accumulation 
of the autophagosome-associated form of the 
autophagy-related protein LC3 (LC3-II, which 
exhibits a higher electrophoretic mobility than LC3-I, 
the form of the protein not associated to 
autophagosomes [37]) (Figure S6D) and by the 
accumulation of LC3 dots in the cytoplasm of GICs 
(Figure S6E), two hallmarks of autophagy [37]. 
Furthermore, we found that pharmacological 
inhibition of lysosomal proteases (by using E64d and 
pepstatin A) in combination with MDK/ALK 
inhibitors led to a further accumulation of LC3-II 
(Figure S6D) in GICs cultures, thereby confirming that 
blockade of the MDK/ALK axis induces dynamic 
autophagy in these cells. Moreover, accumulation of 
LC3 dots upon incubation with an anti-MDK 
antibody for 24 h occurred preferentially in 
NESTIN-positive cells (Figure 4A and 4B) indicating 
that the stimulation of autophagy observed upon 
inhibition of MDK signaling took place in the 
population of cells exhibiting a stem-like phenotype. 
Autophagy is required for the loss of the 
stem-like phenotype evoked by the blockade of 
MDK/ALK axis in GICs 
To analyze the relevance of the early stimulation 
of autophagy in the loss of stem-like properties 
observed in GICs upon blockade of MDK/ALK 
signaling, we analyzed the effect of MDK signaling 
inhibition in GICs cultures expressing a doxycycline- 
inducible shRNA against the autophagy essential 
protein ATG5 [37] (Figure S7A). As shown in Figure 
4C and Figure S7B, MDK neutralization triggered an 
early (24 h) and transient induction of autophagy 
followed by a sustained reduction in the expression of 
the stem-cell markers MSI1 and CD133 in autophagy- 
proficient GH2-GICs but not in ATG5-silenced 
GH2-GICs. Moreover, genetic inhibition of autophagy 
by using the above-described doxycycline- inducible 
shRNA against ATG5 (Figure 4D and Figure S7C) or a 
constitutive shRNA against ATG7 (another essential 
autophagy gene; Figure S7D-E) abrogated the 
inhibitory effect triggered by MDK/ALK pharmaco-
logical inhibition on the self-renewal capacity of GICs 
cultures. Altogether, these results strongly support 
the notion that stimulation of autophagy is required 
for the loss of the stem-like phenotype evoked by the 
blockade of MDK/ALK axis in GICs. 
We next investigated whether MDK/ALK axis 
blockade-triggered autophagy stimulation is respon-
sible for SOX9 degradation in GICs. In line with this 
idea, pharmacological inhibition of protein degrada-
tion through the autophagosome-lysosome pathway 
by using E64d + pepstatin A, or genetic inhibition of 
autophagy by knocking down the expression of ATG5 
(Figure S7F), prevented the decrease of SOX9 protein 
levels triggered by incubation with an anti-MDK 
neutralizing antibody (Figure 4E) or by the pharma-
cological inhibition of ALK (Figure 4F). Similar results 
were obtained by knocking down the expression of 
ATG7 (Figure S7G). These findings demonstrate that 
the blockade of the MDK/ALK axis in GICs triggers 
SOX9 degradation via autophagy stimulation. 
It has been proposed that the targeting and 
subsequent degradation of protein cargos through the 
autophagosome-lysosome pathway involves the 
unspecific incorporation of cytoplasmic or organelle- 
associated proteins into the autophagosome [38]. In 
addition, at least a fraction of cellular proteins can be 
selectively targeted to the autophagosomes - via direct 
interaction with LC3 or other proteins involved in the 
formation of the phagophore (the initial structure that 
gives origin to the autophagosomal membrane) or via 
cargo-transporting proteins [37, 38]. Therefore, next 
we asked whether the autophagic degradation of 
SOX9 observed in GICs upon blockade of the 
MDK/ALK axis was due to the selective targeting of 
this transcription factor to the autophagosome. As 
shown in Supplementary Figure 7H, immunoprecipi-
tation of LC3 from vehicle-treated GH2-GICs pulled 
down SOX9 and this effect was enhanced when 
lysosomal proteases were inhibited, suggesting that 
regulation of SOX9 levels relies on its association with 
the autophagic machinery and further supporting the 
idea that autophagy is involved in the regulation of 
SOX9 levels in GICs. In addition, the interaction of 
SOX9 with the LC3 complex was abolished upon 
blockade of the MDK/ALK axis and the subsequent 
induction of SOX9 autophagic degradation (Figure 
S7H), whereas pharmacological inhibition of the 
lysosomal proteases prevented SOX9 degradation and 
restored the interaction between SOX9 and the LC3 
complex. Likewise, pharmacological blockade of 
lysosomal degradation enhanced the interaction of 
immunoprecipitated SOX9 with the pulled down 
autophagosome-associated form of LC3 upon MDK/ 
ALK inhibition (Figure S7I). Taken together, these 
observations demonstrate that the blockade of the 
MDK/ALK axis in GICs stimulates SOX9 degradation 
through the autophagy-lysosome pathway. 
Blockade of the MDK/ALK axis targets GICs in 
vivo 
To investigate whether blockade of the 
MDK/ALK axis may be used as a strategy to target 
the population of GICs in vivo, we tested the effect of 
some of the ALK inhibitors that are currently being 
used in anticancer therapies. As described above, 
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blockade of ALK using crizotinib inhibited the 
self-renewal capacity of GICs cultures (Figure 2C, 
Figure S4C-D), reduced the expression of several stem 
cell markers (Figure S4E-F) and induced autophagy 
(Figure S6D-E) in cultures of these cells. Similar 
results were obtained with lorlatinib (Figure S4C and 
S8A). Accordingly, treatment with crizotinib or 
lorlatinib alone strikingly reduced the growth of 
GICs-derived tumors (Figure 5A). Moreover, 
treatment with these agents produced a strong 
reduction in the expression of stem cell markers 
(Figure 5B and 5C and Figure S8B-C), supporting the 
idea that ALK pharmacological inhibition reduces the 
population of GICs in vivo. 
Combination therapies based on the blockade 
of the MDK/ALK axis as a strategy to eliminate 
the population of GICs 
Current strategies to treat GBM are based on the 
use of combination therapies. Therefore, we next 
asked whether the administration of inhibitors of the 
MDK/ALK axis may contribute to improve the 
efficacy of current anti-GBM treatments. To test this 
hypothesis, we initially selected temozolomide (TMZ, 
the benchmark agent for the management of GBM) as 
the effect of the combination of crizotinib and TMZ on 
GBM patients is currently being tested in a clinical 
study (clinical trials.gov identifier: NCT02270034). 
The inhibitory effect of crizotinib on the self-renewal 
capacity of GICs was dramatically enhanced by the 
co-administration of TMZ (Figure 5D) leading to an 
almost complete elimination of the population of 
GICs. Likewise, apoptosis was strikingly activated in 
GICs cultures upon the combined administration of 
these two agents (Figure S9A). Similar results were 
obtained when we tested the combined effect of 
MDK/ALK axis inhibitors and cannabinoids, a novel 
family of potential anticancer agents [39, 40] that have 
been shown to synergize with ALK inhibitors in 
differentiated glioma cells [13, 39, 40]. The combined 
administration of submaximal doses of crizotinib or of 
an anti-MDK neutralizing antibody and Δ9-tetra-
hydrocannabinol (THC, the main active ingredient of 
marijuana) strongly enhanced the effect of the 
individual treatments in the self-renewal capacity of 
GICs, leading to an almost complete elimination of the 
population of GICs in vitro (Figure S9B-C). Likewise, 
the combined administration of MDK/ALK axis 
inhibitors together with a mixture of THC and canna-
bidiol (CBD, another active ingredient of Cannabis 
sativa) at a 1:1 ratio exerted a similar inhibitory effect 
on the generation of neurospheres and the self- 
renewal capacity of GICs (Figure 5E). Furthermore, 
we found that the combined administration of crizo-
tinib, or an anti-MDK neutralizing antibody and THC, 
but not treatment with these agents individually, 
triggered apoptosis and GICs death (Figure S9D).  
Therefore, next we tested the effect of the 
combined administration of these agents in xenografts 
generated with GICs. Treatment with crizotinib and 
TMZ (Figure 5F) produced a much stronger reduction 
on the growth of xenografts generated with 
12O12-GICs than the treatments with each of those 
agents alone. Likewise, apoptosis was activated to a 
much higher extent in samples derived from tumors 
that had received the combined treatments than in 
those that had been treated with crizotinib or TMZ 
alone (Figure S9E). Furthermore, a similar enhanced 
anticancer activity was observed when lorlatininb was 
combined with TMZ (Figure S9F). 
Altogether, these findings strongly support the 
notion that MDK/ALK axis inhibition-based 
combinational therapies can be used as a strategy to 
deplete the population of GICs and improve the 
efficacy of current anti-GBM therapies. 
Discussion 
Work performed during the last decades has 
unraveled the importance of “cancer stem-like cells” 
in the generation and progression of many different 
cancers. In the case of GBM, the very high frequency 
of relapses and resistance to conventional therapies 
typical of these tumors has led to postulate that GICs 
play a crucial role in their aggressive evolution. GBMs 
are highly heterogeneous and contain cells with 
different degrees of differentiation, being the 
subpopulation of GICs a very minor proportion of 
cells within the tumor mass [6, 7]. Thus, the 
stimulatory effect evoked by different growth factors 
on GICs seems to be of crucial importance to preserve 
their self-renewal capacity and therefore for the 
maintenance of this sub-population within the tumor 
mass [6, 7, 41, 42]. Results presented in this study now 
demonstrate that the neurotrophic factor MDK plays a 
direct role in the regulation of the self-renewal and 
tumorigenic capacity of GICs, supporting the notion 
that increased levels of this factor decisively 
contribute to maintain this population. In line with 
this idea, increased levels of MDK correlate with 
lower survival of GBM patients which suggests that 
the upregulation of this factor may contribute to 
enhance the aggressiveness of GBMs by maintaining/ 
expanding the population of GICs. In addition, 
previous observations had shown that enhanced 
MDK expression in differentiated glioma cells 
promotes resistance to the treatment with 
cannabinoids and other anticancer agents [12, 13]. Of 
note, recent results have shown that MDK plays a 
paracrine role in the regulation of lymphatic 
endothelial cells during melanoma metastasis [43].  
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Figure 5. Combination of MDK/ALK inhibitors with cannabinoids and TMZ strongly reduces the growth of GICs-derived xenografts. (A) Effect of daily oral administration 
of crizotinib (12.5 mg/kg, upper panel) or lorlatinib (25 mg/kg, bottom panel) on the volume of glioma xenografts generated by subcutaneous injection of 2 x 106 12O12-GICs (mean ± SEM on 
the last day of the treatment). **P < 0.01 from 12O12 vehicle-treated tumors. (B) Effect of daily oral administration of crizotinib (12.5 mg/kg) on the mRNA levels of NESTIN, MUSASHI-1 
(MSI1), SOX2 and SOX9 (as determined by qPCR) of glioma xenografts generated by subcutaneous injection of 2 x 106 12O12-GICs (mean ± SEM). *P < 0.05 from 12O12 vehicle-treated 
tumors. (C) Effect of daily oral administration of lorlatinib (25 mg/kg) on the protein levels (as determined by Western blot) of NESTIN, MUSASHI-1 (MSI1), SOX2 and SOX9 in the tumor 
xenografts (V1-V6: vehicle-treated animals; L1-L5: lorlatinib-treated animals). (D) Effect of the treatment with crizotinib (0.5 µM) and TMZ (100 μM, upper panel or 20 μM bottom panel) on 
the self-renewal ability (as determined by LDA) of GH2 (upper panel) or 12O12 (bottom panel)-GICs (n=2). Full χ2 statistical analysis is included in LDA statistics section within the 
supplementary materials. (E) Effect of the treatment with THC:CBD (2.5 μM THC + 2.5 μM CBD) and MDK Ab. (40 μg/ml, left panel) or crizotinib (CZT, 0.25 µM, right panel) on the total 
number of cells (upper panels) and self-renewal capacity (bottom panels) of 12O12-GICs (n=3). **P < 0.01 and ***P < 0.001 from vehicle-treated cells; ###P < 0.001 from THC + CBD-treated 
cells; &P < 0.05 or &&P < 0.01 from MDK Ab.-treated cells or crizotinib-treated cells. Full χ2 statistical analysis is included in LDA statistics section within the supplementary materials. (F) Effect 
of the treatment with crizotinib (12.5 mg/kg daily oral administration) and TMZ (5 mg/kg twice a week IP administration) on the growth of glioma xenografts generated by subcutaneous 
injection of 2 x 106 12O12-GICs [mean ± SEM; n=5-6 mice for each condition]. Representative pictures of the tumor xenografts in the last day of the treatment are shown for each 
experimental condition. Symbols of significance are omitted for clarity except when the combined-treatment was significantly different from vehicle and each individual treatment (*P < 0.05 
or **P <0.01 from each individual treatment). The rest of the statistical analysis can be found in Supplementary materials. 
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Likewise, it was recently reported that 
p53-dependent MDK-induction upon DNA damage 
in gliomas promoted M2 polarization of microglia 
and that this event would play a relevant role on the 
remodeling of the tumor microenvironment [44]. 
Taken together, these observations suggest that part 
of the oncogenic effects of MDK in GBM may also be 
due to the capacity of this factor to interact with the 
stroma. Moreover, altogether these observations point 
to the potential utilization of MDK as a biomarker of 
bad prognosis and resistance to therapies in GBM. 
Our findings also show that MDK effects on 
GICs rely on ALK stimulation. These observations are 
in line with previous work by our group showing that 
MDK expression promoted resistance to anticancer 
agent-induced differentiated glioma cell death via this 
tyrosine kinase receptor rather than PTPRz or other 
receptors that have been proposed to mediate MDK 
actions in other contexts [10]. Nevertheless, it cannot 
be discarded that some of these receptors may also 
contribute - at least to some extent - to MDK actions in 
gliomas or GICs. 
ALK has been shown to undergo gain of 
function mutations in different cancer types including 
non-small-cell lung cancer, anaplastic large cell 
lymphomas and neuroblastoma although not – or 
with a very low frequency - in gliomas [32]. Results 
presented here, together with previous observations 
obtained by other groups [45] indicate that enhanced 
ligand-triggered ALK stimulation rather than genetic 
alterations on this receptor would be responsible for 
the effects observed in GICs and therefore in GBM 
biology.  
Results from the current study also demonstrate 
that the mechanism by which the MDK/ALK axis 
regulates GICs biology is based on the control of the 
stability of SOX9. The SOX family of transcription 
factors plays a crucial role in the regulation of 
stem-cell biology [35, 46]. Results obtained in this 
work are in line with the idea that these transcription 
factors, and specifically SOX9, are essential for the 
maintenance of the stem-like properties and 
self-renewal capacity of GICs. Our findings reveal 
that the autophagosome-lysosome pathway rather 
than other mechanisms that have been previously 
shown to be involved in regulating SOX9 levels [46] is 
responsible for the control of SOX9 stability in GICs. 
Thus, the blockade of the signal evoked by 
MDK/ALK in GICs triggers a transient activation of 
autophagy that is responsible for the selective 
degradation of SOX9 rather than of other SOX 
transcription factors. Whether MDK/ALK signaling 
controls the stem like properties of GICs via the 
regulation of a specific subset of SOX9-regulated 
genes is an interesting possibility that remains to be 
investigated. 
Depending on the stage of the tumor and cancer 
type, autophagy has been shown to play oncogenic or 
onco-suppressor functions [47, 48]. Our data support 
the idea that MDK/ALK signaling contributes to GICs 
maintenance by suppressing the autophagic 
degradation of SOX9. It is worth noting that, although 
autophagy has been proposed to play a supportive 
role in cancer stem cells [47, 49] including GBM [50], 
we found that genetic or pharmacological blockade of 
autophagy does by itself significant alter the self- 
renewal capacity of GICs cultures. These apparently 
contradictory observations may be reconciled in a 
model in which the selectivity of the cargos targeted 
for degradation to the autophagosome-lysosome 
pathway or the intensity/duration with which this 
cellular process is stimulated determine the role and 
outcome of the autophagic process. In any case 
further research is required to clarify the role of 
autophagy in the regulation of glioma generation and 
progression and especially in GICs.  
Our work also demonstrates that the 
pharmacological targeting of the MDK/ALK axis 
efficiently acts on the population of GICs in vitro and 
in tumor xenografts. Moreover, blockade of 
MDK/ALK signaling enhances the response of GICs 
cultures to treatment with TMZ, the benchmark agent 
for the management of GBM [2, 3], as well as to 
treatment with THC or a combination of THC:CBD 
[51]. Thus, unlike individual treatments (and 
specifically blockade of MDK/ALK signaling) that 
produced a cytostatic effect in GICs cultures, the 
combined administration of these drugs induced the 
apoptotic death of GICs leading to an almost complete 
eradication of this population in vitro and to a 
strikingly enhanced anticancer activity in vivo. These 
observations support the notion that inhibition of the 
MDK/ALK axis is a useful strategy to target the 
population of GICs and to improve the response to 
other antineoplastic agents. Specifically, in this work 
we tested the activity of two ALK inhibitors 
(crizotinib and lorlatinib) that are currently used in 
the clinical practice for the management of other 
malignancies [34]. These findings together with the 
good safety profile of lorlatinib and especially 
crizotinib compared with other RTK inhibitors helped 
to set the bases for a clinical study that is currently 
evaluating the safety and activity of crizotinib 
together with temozolomide and radiotherapy in 
newly-diagnosed glioblastoma (ClinicalTrials.gov 
Identifier: NCT02270034). 
In summary, findings presented in this work 
show that the MDK/ALK axis plays a key role in the 
regulation of GICs self-renewal and tumorigenic 
capacity by controlling the selective autophagic 
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degradation of SOX9. In addition, our data provide 
strong preclinical evidence that inhibition of this 
signaling axis may be a potential therapeutic strategy 
to eliminate this cell population. These findings may 
provide the rational for the development of novel 
therapeutic strategies against GBM based on the 
blockade of the MDK/ALK axis with the aim of 
targeting the population of GICs. 
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